Close Menu

While a number of proteomics firms continue to knock on the doors of big pharma for business, many pharmaceutical companies have chosen to integrate proteomics into their own R&D pipeline. In a morning session at the HUPO meeting in Versailles last November, scientists from Bristol-Myers Squibb, Novartis, Millennium Pharmaceuticals, and Celera gave participants a glance of the way they are using proteomics techniques to discover new drug targets and biomarkers for specific diseases.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Springer Nature announces €9,500 fee to make papers open-access in Nature and its family of journals.

Librarians have concluded that notebooks that belonged to Charles Darwin that were thought to have been lost were actually likely stolen, CNN reports.

An early SARS-CoV-2 alteration may have enabled it to spread more easily, according to the New York Times.

In PNAS this week: ultrarare variants contribute to aging-related hearing loss, telomeres of cells infected with herpesvirus, and more.